Shares of Evogene Ltd. (NASDAQ:EVGN) have been assigned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.

Brokers have set a 12-month consensus price target of $8.00 for the company and are anticipating that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also given Evogene an industry rank of 108 out of 265 based on the ratings given to its competitors.

A hedge fund recently raised its stake in Evogene stock. Vanguard Group Inc. lifted its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 4.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 436,225 shares of the biotechnology company’s stock after purchasing an additional 17,391 shares during the period. Vanguard Group Inc. owned approximately 1.70% of Evogene worth $2,443,000 at the end of the most recent reporting period. Institutional investors own 30.99% of the company’s stock.

Shares of Evogene (NASDAQ EVGN) traded up $0.06 during mid-day trading on Wednesday, hitting $3.43. 7,111 shares of the stock were exchanged, compared to its average volume of 13,049. Evogene has a 12 month low of $3.37 and a 12 month high of $5.84.

ILLEGAL ACTIVITY NOTICE: “Zacks: Evogene Ltd. (EVGN) Given Consensus Recommendation of “Hold” by Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/13/zacks-evogene-ltd-evgn-given-consensus-recommendation-of-hold-by-brokerages.html.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.